Short stature – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:02:46 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Short stature – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature https://clinicaltrials.eu/trial/study-of-lonapegsomatrin-and-somatropin-in-children-and-adolescents-with-short-stature-or-growth-failure-due-to-turner-syndrome-shox-deficiency-sga-or-idiopathic-short-stature/ Wed, 29 Apr 2026 15:09:09 +0000 https://clinicaltrials.eu/trial/study-of-lonapegsomatrin-and-somatropin-in-children-and-adolescents-with-short-stature-or-growth-failure-due-to-turner-syndrome-shox-deficiency-sga-or-idiopathic-short-stature/ This study is being conducted to evaluate the efficacy and safety of lonapegsomatropin compared to somatropin. The research focuses on children and adolescents who experience growth failure or short stature, which means they are shorter than expected for their age. These conditions may be caused by several different disorders, such as Turner Syndrome, SHOX Deficiency, being small for gestational age, or idiopathic short stature, which is when short height occurs without a known medical cause.

Participants in the study will receive either lonapegsomatropin or somatropin through a subcutaneous injection, which is a method of delivering medication into the fatty layer just under the skin. The goal is to compare a weekly injection of the new medication to the daily use of the standard treatment. During the course of the study, height and growth progress will be monitored over a period of time to see how the different treatments affect development.

]]> Study on the Effects of Vosoritide for Children with Idiopathic Short Stature https://clinicaltrials.eu/trial/study-on-the-effects-of-vosoritide-for-children-with-idiopathic-short-stature/ Wed, 29 Apr 2026 15:06:05 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-vosoritide-for-children-with-idiopathic-short-stature/ This clinical trial is focused on studying a condition known as Idiopathic Short Stature (ISS) in children. This condition is characterized by a height significantly shorter than average for a child’s age and sex, without a known cause. The study will use a treatment called vosoritide, which is a modified form of a natural protein in the body. Vosoritide is administered as a solution for injection and is being tested to see if it can help improve growth in children with ISS.

The purpose of the study is to evaluate the effects of different doses of vosoritide compared to a placebo over a period of six months. In the long-term phase, the study will compare the effects of vosoritide with human growth hormone (hGH) on children’s height and growth patterns. The study will involve regular assessments of the children’s growth, including changes in height and growth rates, over a period of up to four years.

Participants in the study will receive either vosoritide or a placebo through subcutaneous injections, which means the injection is given under the skin. The study aims to find the most effective dose of vosoritide and to understand its long-term benefits and safety for children with ISS. Regular monitoring will be conducted to track any side effects and to measure changes in growth and development.

]]> Study on the Effects of Somatropin and Letrozole in Boys with Short Predicted Height https://clinicaltrials.eu/trial/study-on-the-effects-of-somatropin-and-letrozole-in-boys-with-short-predicted-height/ Wed, 29 Apr 2026 15:03:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-somatropin-and-letrozole-in-boys-with-short-predicted-height/ This clinical trial is focused on boys with a condition known as short predicted height, which means they are expected to be shorter than average when they grow up. The study is examining the effects of two treatments: Omnitrope, which is a form of growth hormone, and Letrozole, an aromatase inhibitor. Aromatase inhibitors are medications that can help increase height by affecting hormone levels during puberty.

The purpose of the study is to see if boys who receive a combination of both Omnitrope and Letrozole during puberty will grow taller than those who receive only Omnitrope. The study will last for four years, during which participants will receive their assigned treatment. The growth of the boys will be monitored to determine if the combination therapy leads to a greater increase in height compared to the growth hormone alone.

Participants in the study will receive their treatments either as a solution for injection in the case of Omnitrope or as film-coated tablets for Letrozole. The study aims to provide valuable information on the effectiveness and safety of these treatments in helping boys with short predicted height achieve a taller adult height.

]]> Study on the Effects of Somapacitan and Somatropin in Children with Short Stature Born Small for Gestational Age Without Catch-Up Growth by Age 2 https://clinicaltrials.eu/trial/study-on-the-effects-of-somapacitan-and-somatropin-in-children-with-short-stature-born-small-for-gestational-age-without-catch-up-growth-by-age-2/ Wed, 29 Apr 2026 14:29:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-somapacitan-and-somatropin-in-children-with-short-stature-born-small-for-gestational-age-without-catch-up-growth-by-age-2/ This clinical trial is focused on children who were born small for gestational age (SGA) and have not experienced catch-up growth by the age of two or older. The study is evaluating the effects and safety of a new treatment called somapacitan, which is given once a week, compared to a daily treatment with Norditropin®. Both treatments are designed to help improve growth in children with short stature due to being born SGA.

The purpose of the study is to assess how well somapacitan works in promoting growth compared to Norditropin®. Participants in the study will receive either somapacitan or Norditropin® through a pen-injector, which is a device used to inject the medication under the skin. The study will last for a period of time during which the growth of the children will be monitored and compared between the two treatment groups.

Throughout the study, researchers will observe changes in the children’s height and other growth-related factors. The study aims to provide valuable information on the effectiveness and safety of somapacitan as a treatment option for children with growth challenges due to being born SGA. This research could potentially lead to new treatment options for children who need help with their growth development.

]]> Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature https://clinicaltrials.eu/trial/study-comparing-somapacitan-and-somatropin-for-growth-in-children-with-short-stature-due-to-small-for-gestational-age-turner-syndrome-noonan-syndrome-or-idiopathic-short-stature/ Wed, 29 Apr 2026 14:27:17 +0000 https://clinicaltrials.eu/trial/study-comparing-somapacitan-and-somatropin-for-growth-in-children-with-short-stature-due-to-small-for-gestational-age-turner-syndrome-noonan-syndrome-or-idiopathic-short-stature/ This clinical trial is focused on children with short stature, which means they are shorter than most children their age. The study includes children who were either born small for their age, or have conditions like Turner syndrome, Noonan syndrome, or idiopathic short stature, which means the cause of their short stature is unknown. The trial is testing a new treatment called somapacitan, which is given once a week, and comparing it to a daily treatment called Norditropin®. Both treatments are designed to help children grow taller.

The purpose of the study is to see if the once-weekly somapacitan is as effective as the daily Norditropin® in helping children grow. The study will last for a period of time, during which children will receive either somapacitan or Norditropin®. The somapacitan is administered using a special pen-injector called the PDS290 pen-injector, which is a pre-filled device that makes it easier to give the injection. The study will monitor the children’s growth over time, specifically looking at how fast they grow in height.

Throughout the study, researchers will also keep an eye on the long-term safety of somapacitan. They will measure various health indicators, such as changes in bone age and levels of certain substances in the blood, like IGF-I and IGFBP-3, which are related to growth. The study aims to provide valuable information on whether somapacitan can be a safe and effective option for children with short stature conditions.

]]> Study on the Safety and Effectiveness of Somapacitan for Children with Short Stature Due to Noonan Syndrome, Turner Syndrome, Small for Gestational Age, or Idiopathic Short Stature https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-somapacitan-for-children-with-short-stature-due-to-noonan-syndrome-turner-syndrome-small-for-gestational-age-or-idiopathic-short-stature/ Wed, 29 Apr 2026 14:24:41 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-somapacitan-for-children-with-short-stature-due-to-noonan-syndrome-turner-syndrome-small-for-gestational-age-or-idiopathic-short-stature/ This clinical trial is focused on studying the safety and effectiveness of a medication called Somapacitan in children who have difficulty growing. The study includes children with conditions such as Turner syndrome, Noonan syndrome, being born small for gestational age, or having idiopathic short stature, which means short stature without a known cause. Somapacitan is given as a solution for injection under the skin, using a special pen-injector designed for single patient use.

The purpose of the study is to evaluate how safe Somapacitan is and how well it works in helping children grow. Participants in the study will receive the medication once a week. The study will monitor the number of any adverse events, which are unexpected medical problems, over a period of time. The study will also look at how the children’s height changes during the study.

The study will take place over several weeks, with regular check-ups to monitor the children’s growth and any side effects they might experience. The goal is to gather information on how Somapacitan affects growth in children with these specific conditions, providing valuable insights into its potential benefits and safety.

]]>